Cefadroxil monohydrate
Executive Summary
International Trade Commission grants Bristol-Myers Squibb temporary relief Jan. 10 following a recent federal circuit court determination that the company's disputed '657 patent is "likely to be sustained" ("The Pink Sheet" Dec. 18, T&G-4). The ITC issued a cease and desist order prohibiting domestic marketing of the antibiotic by Biocraft, Kalipharma and Purepac unless a bond is posted for 68% of the "entered value of the imported articles," ITC said in a notice published in the Jan. 18 Federal Register. The commission also gave a temporary limited exclusion order prohibiting foreign manufacturers from importing the product without posting bond for 68% of its value. The orders will remain effective until the ITC reaches its final determination, due March 15.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.